RETATRUTIDE MAY OFFER MORE WEIGHT LOSS THAN ANY CURRENT MEDICATION ON THE MARKET
Eli Lilly, the developer of Retatrutide reported on their Phase 2 study Trial- Triple Hormone-Receptor Agonist Retatrutide for Obesity
Background
Retatrutide is an agonist of the glucagon-like peptide1, and glucagon receptors. its dose response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are assessed in this study. they conducted a phase 2, double blind, randomized, placebo controlled trial of adults who had a bmi (body mass index) of 30 or higher or who had a bmi between 27 and 30 with at least one other weight related medical condition in order to qualify for the study. The study participants received the treatment of a subcutaneous weekly injection of retatrutide with a starting dose of either 1mg, 2mg, 4 mg, 8mg,12 mg or placebo. They continued on the retatrutide for 48 weeks . The study measured their percentage of weight loss at 24 weeks and then again at 48 weeks. their end points (positive beneficial response) to be measured and characterized were weight loss of 5% or more, 10% or more, or 15% or more. The medications safety was also assessed.
PARTICIPANTS AND RESULTS
The study subjects were between 18 and 75 years old and had a body-mass index (bmi) of between 30 and fifty. potential subjects were excluded from the study if they had diabetes, previous or planned surgical treatment for obesity, and treatment with weight loss medications within 3 months prior to the beginning of the study, as well as a significant recent change in their body weight.
There were 338 adult study participants divided nearly evenly between men and women.
The study results showed the participants administered retatrutide consistently lost more weight than those given a placebo, and that those who took hgiher doses lost more than those who took the lower doses. measured at 24 weeks those who took the 1 mg dose lost 7.2% of their body weight , those in the 4 mg group lost 12.9 % the 8 mg group lost 17.3%, and those given the highest dose–the 12mg group lost 17.5% of their body weight.
Measured again at 48 weeks, the 1-mg group lost 8.7 % of their body weight, the 4-mg group lost 17.1% the 8-mg group lost 22.8%, and finally those given the highest dose, 12mg lost 24.2% of their body weight.
Looking at it another way, at 48 weeks, a weight loss of 5% or more was achieved by 92% of the 4 mg group, and all participants-100% % of the 8mg group and the 12mg group. A weight reduction of 10% or more was achieved by 75% of the 4mg group, 91% of the 8mg group and 93% the subjects given the 12mg. Finally , subjects for whom greater than 15% of their body weight occurred was seen in 60% in the 4mg group, 75% in the 8mg group and 83% in the 12mg group
The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). There was also dose -dependent asymptomatic increase in heart rate which peaked at 24 weeks and declined thereafter.
Conclusions
Overall study presents a clearly significant reduction in body weight for those treated with retatrutide treatment for 48 weeks in all doses tested. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.)
Eli LIlly in their review of the problem of obesity states that “Obesity is a chronic, treatable, neurometabolic disease” that affects a large segment of the population both in the US and worldwide and the problem is getting more and more prevalent. 1 Recent advances in the development of medications for agents for the treatment of obesity were modest have been greatly advanced with the advent of GLP-1 receptor antagonists such as semaglutide and tirzepatide.2-7 https://drsobo.com/weight-loss-injections-lower-cancer-risk/
Several other GLP-1–GCG and GIP–GLP-1–GCG receptor agonists are currently in clinical development, given the premise that incorporating GCG receptor agonism may further reduce energy intake, increase energy expenditure, or both, thus potentially enhancing efficacy.9-11 Retatrutide (LY3437943; Eli Lilly) is a peptide with affinity for 3 receptors- GIP, GLP-1, and GCG.The clinical effects are dose-proportional both in the effect for the intended purpose as well as for side effects which may occur. Retatrutide has a half life in the body of 6 days,13 which allows for its weekly administration.
Cardiometabolic Risk Factors and Participant-Reported Outcomes https://drsobo.com/tirzepatide-preventspre-diabetes-to-diabetes/
Treatment with retatrutide was associated with improvements in cardiometabolic measures including systolic and diastolic blood pressure, and levels of HgbA1C (glycated hemoglobin), fasting glucose, insulin, and lipids at weeks 24 and 48 . At week 48, 72% of the participants who had prediabetes at baseline in the retatrutide groups had reverted to normal glucose levels (glycated hemoglobin, <5.7%), Improvements in blood pressure within the 48-week treatment period resulted in discontinuation of at least one antihypertensive medication in 41% of the participants in the combined 8-mg group and in 30% of the participants in the 12-mg group.
Safety The most frequent side effects were gastrointestinal-nausea, diarrhea, vomiting-constipation. These occurred more frequently with the higher doses 8 and 12mg as sthe subjects increased their dosing sequentially. 16 % discontinued use of the medication as a result of side effects.
This study was classified as a phase 2 trial. A larger phase 3 trial will be conducted prior to the application to the FDA for the medication to be approved as a new treatment.The conclusion of thsi trial demonstrated that with the 12mg dose of retatrutide a GIP-GLP-1,GCG receptor triple agonist resulted in a mean weight reduction of 24.2%. this is a result which surpasses previous medications which are currently approved and on sale in the U.S. for the treatment of obeisty. It is very important to note that the study subjects trajectory of weight loss showed that over the 48 week trial period there was no plateau regarding the weight loss. The participants continued to lose weight in the latter part of the 48 weeks during which they were assessed.And it reasonable to infer that they would have continued to lose even more weight if they were to continue receiving the treatment beyond the 48 week study period. This would be consistent with what has be see in the study of similar medications currently on the market.
Weight reductions among the participants who received retatrutide were accompanied by improvements in cardiometabolic measures, including blood pressure, HgbA1C readings,fasting glucose, insulin, and lipid levels. Also,72% of the participants who had prediabetes at baseline reverted to normal glucose and HgbA1C levels with retatrutide treatment. The primary factor that led to these findings was the substantial degree of weight loss.
The safety profile of retatrutide was consistent with reported phase 1 findings in persons with type 2 diabetes13 and similar to those of therapies based on GLP-1 or GIP–GLP-1 for the treatment of type 2 diabetes or obesity.3,4 Transient, mostly mild-to-moderate gastrointestinal events were the most frequently reported adverse events, occurring primarily during dose escalation. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
In conclusion, this phase 2 trial showed that once-weekly treatment with retatrutide results in substantial weight reduction at 24 and 48 weeks, with dose-dependent efficacy. These results warrant further investigation as will be done in the planned phase 3 trial.
